These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 12523881

  • 1. Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study).
    Pfeiffer N, Grierson I, Goldsmith H, Appleton P, Hochgesand D, Winkgen A.
    Arch Ophthalmol; 2003 Jan; 121(1):23-31. PubMed ID: 12523881
    [Abstract] [Full Text] [Related]

  • 2. Morphometric effects of long-term exposure to latanoprost.
    Cracknell KP, Grierson I, Hogg P.
    Ophthalmology; 2007 May; 114(5):938-48. PubMed ID: 17292473
    [Abstract] [Full Text] [Related]

  • 3. Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies.
    Cracknell KP, Grierson I, Hogg P, Appleton P, Pfeiffer N.
    Exp Eye Res; 2003 Dec; 77(6):721-30. PubMed ID: 14609560
    [Abstract] [Full Text] [Related]

  • 4. Latanoprost-induced changes in the iris and trabeculum: an electron-microscopic morphological study.
    Yildirim N, Sahin A, Kara S, Baycu C.
    Int Ophthalmol; 2010 Feb; 30(1):93-7. PubMed ID: 19139827
    [Abstract] [Full Text] [Related]

  • 5. Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 study.
    Pfeiffer N, Grierson I, Goldsmith H, Hochgesand D, Winkgen-Böhres A, Appleton P.
    Arch Ophthalmol; 2001 Feb; 119(2):191-6. PubMed ID: 11176979
    [Abstract] [Full Text] [Related]

  • 6. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.
    Albert DM, Gangnon RE, Zimbric ML, Damico CM, Fisher MR, Gleiser J, Grossniklaus HE, Green WR.
    Arch Ophthalmol; 2004 Nov; 122(11):1680-5. PubMed ID: 15534130
    [Abstract] [Full Text] [Related]

  • 7. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report.
    Tsai JC, Sivak-Callcott JA, Haik BG, Zhang J, McLean IW.
    J Glaucoma; 2001 Oct; 10(5):411-3. PubMed ID: 11711840
    [Abstract] [Full Text] [Related]

  • 8. Analysis of irises with a latanoprost-induced change in iris color.
    Arranz-Marquez E, Teus MA, Saornil MA, Mendez MC, Gil R.
    Am J Ophthalmol; 2004 Oct; 138(4):625-30. PubMed ID: 15488791
    [Abstract] [Full Text] [Related]

  • 9. Histology and fine structure of the iris and outflow system following latanoprost therapy.
    Grierson I, Pfeiffer N, Cracknell KP, Appleton P.
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S176-84. PubMed ID: 12204715
    [Abstract] [Full Text] [Related]

  • 10. A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides.
    Albert DM, Gangnon RE, Grossniklaus HE, Green WR, Darjatmoko S, Kulkarni AD.
    Arch Ophthalmol; 2008 May; 126(5):626-31. PubMed ID: 18474771
    [Abstract] [Full Text] [Related]

  • 11. Iris morphology.
    Teus MA, Arranz-Marquez E.
    Ophthalmology; 2008 Feb; 115(2):418-9; author reply 419-20. PubMed ID: 18243921
    [No Abstract] [Full Text] [Related]

  • 12. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
    Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE.
    Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
    [Abstract] [Full Text] [Related]

  • 13. Melanin in the trabecular meshwork is associated with age, POAG but not Latanoprost treatment. A masked morphometric study.
    Cracknell KP, Grierson I, Hogg P, Majekodunmi AA, Watson P, Marmion V.
    Exp Eye Res; 2006 Jun; 82(6):986-93. PubMed ID: 16297910
    [Abstract] [Full Text] [Related]

  • 14. Effect of additive preoperative latanoprost treatment on the outcome of filtration surgery.
    Berthold S, Pfeiffer N.
    Graefes Arch Clin Exp Ophthalmol; 2006 Aug; 244(8):1029-34. PubMed ID: 16341541
    [Abstract] [Full Text] [Related]

  • 15. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma.
    Alm A, Schoenfelder J, McDermott J.
    Arch Ophthalmol; 2004 Jul; 122(7):957-65. PubMed ID: 15249358
    [Abstract] [Full Text] [Related]

  • 16. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes.
    Latanoprost-Induced Iris Pigmentation Study Group.
    Jpn J Ophthalmol; 2006 Jul; 50(2):96-9. PubMed ID: 16604382
    [Abstract] [Full Text] [Related]

  • 17. Incidence of iris colour change in latanoprost treated eyes.
    Teus MA, Arranz-Márquez E, Lucea-Suescun P.
    Br J Ophthalmol; 2002 Oct; 86(10):1085-8. PubMed ID: 12234883
    [Abstract] [Full Text] [Related]

  • 18. The effect of latanoprost on aqueous humor PGF2alpha levels in glaucoma patients.
    Güven D, Karakurt A, Saban E, Hasiripi H.
    Int Ophthalmol; 1999 Oct; 23(2):91-6. PubMed ID: 11196126
    [Abstract] [Full Text] [Related]

  • 19. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA, Travoprost Study Group.
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [Abstract] [Full Text] [Related]

  • 20. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM, McGavin JK, Culy CR, Ibbotson T.
    Drugs Aging; 2003 Oct; 20(8):597-630. PubMed ID: 12795627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.